ADB-103 is our development program for the treatment of Chronic Hip Osteoartritis Pain. Our novel, non-opioid JDNI8 rdHSV-CA8* non-toxic gene therapy (ADLR-1001) is designed to locally target through intra-articular injection (inside the hip joint) the peripheral sensory nerve fibers that are hyper-excitable due to sensitization and inflammation.  OA pain is a complex (e.g.: neuropathic and inflammatory) pain disorder.

The ADB-103 Program stands to benefit greatly from the ADB-102 Program’s NIH UG3/UH3 HEAL grant which funds development in Chronic OA Knee Pain through IND and First-in-Human clinical study. Scope of the ADB-102 Program Award includes manufacturing/process development, CMC, and formal GLP toxicology studies.

Validation in Osteoarthritis Knee Pain Opens the Pipeline Expansion Opportunity for Chronic Hip Osteoarthritis Pain

Osteoarthritis (OA) Hip Pain

OA Hip Pain is a common degenerative joint condition characterized by the breakdown of cartilage in the knee joints. This leads to pain, stiffness, and reduced mobility, particularly during activities like walking or climbing stairs. Current treatment options involve a combination of lifestyle modifications, pain relievers, and, in severe cases, surgical interventions like hip replacement to alleviate symptoms, regain funtionality and improve quality of life.

• ~30% have hip osteoarthritis (~10 million patients)
• Median onset at age 55, ~60% female
• 40%-50% of Hip OA patients develop bilateral OA over 10-12 years

Joint replacement is the ultimate treatment for many patients

• ~400,000 hip replacements annually in the U.S.

Many patients are not surgical candidates

• E.g. patients with co-morbidities and obese patients​

Limited pain ​treatment options

• Acetaminophen / NSAIDs​
• Intra-articular Steroid Injections
• Opioids
• Hyaluronate Injections​
• Hip Replacement

1. CDC: https://www.cdc.gov/arthritis/basics/osteoarthritis